A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors
KK Wong, PM Fracasso, RM Bukowski, TJ Lynch… - Clinical cancer …, 2009 - AACR
Purpose: The dose-limiting toxicities, maximum tolerated dose, pharmacokinetic profile, and
preliminary antitumor activity of neratinib (HKI-272), an irreversible pan ErbB inhibitor, were …
preliminary antitumor activity of neratinib (HKI-272), an irreversible pan ErbB inhibitor, were …
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial
…, C Ma, PM Fracasso, I Zoberi, M Taylor… - The lancet …, 2010 - thelancet.com
Background Treatment with bisphosphonates decreases bone loss and can increase disease-free
survival in patients with breast cancer. The aim of our study was to assess the effect of …
survival in patients with breast cancer. The aim of our study was to assess the effect of …
[HTML][HTML] Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
…, PM Fracasso, E Norry, D Williams, M Druta… - Nature medicine, 2023 - nature.com
Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy.
Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell …
Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell …
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or …
…, MMO Baekelandt, AN Gordon, PM Fracasso… - Journal of Clinical …, 2008 - ascopubs.org
Purpose To compare the safety and efficacy of carboplatin and paclitaxel administered with
or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with …
or without the multidrug resistance modulator valspodar (PSC 833) in untreated patients with …
A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing
PM Fracasso, H Burris III, MA Arquette, R Govindan… - Clinical cancer …, 2007 - AACR
Purpose: This phase 1 study evaluated the pharmacokinetic and pharmacodynamic effects
of cetuximab on patients with epithelial malignancies. Experimental Design: Following a skin …
of cetuximab on patients with epithelial malignancies. Experimental Design: Following a skin …
Chemotherapeutic attack of hypoxic tumor cells by the bioreductive alkylating agent mitomycin C
SR Keyes, DC Heimbrook, PM Fracasso… - Advances in enzyme …, 1985 - Elsevier
Since the cure of solid tumors is limited by the presence of cells with low oxygen contents,
we have approached the development of treatment regimens and of new drugs for these …
we have approached the development of treatment regimens and of new drugs for these …
Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy …
…, BR Nathan, MD Ward, JE Boyer, PM Fracasso - Clinical Colorectal …, 2014 - Elsevier
Discussion Reversible posterior leukoencephalopathy syndrome is a clinical radiographic
syndrome of insidious onset of headache, confusion or decreased level of consciousness, …
syndrome of insidious onset of headache, confusion or decreased level of consciousness, …
[HTML][HTML] A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
…, J Dancey, H Piwnica-Worms, PM Fracasso - Breast cancer research …, 2013 - Springer
Mutations in TP53 lead to a defective G1 checkpoint and the dependence on checkpoint
kinase 1 (Chk1) for G2 or S phase arrest in response to DNA damage. In preclinical studies, …
kinase 1 (Chk1) for G2 or S phase arrest in response to DNA damage. In preclinical studies, …
A phase II study of bortezomib in the treatment of metastatic malignant melanoma
…, W Sharfman, M Albertini, W Maples, PM Fracasso… - Cancer, 2005 - Wiley Online Library
BACKGROUND Bortezomib is a proteasome inhibitor with manageable clinical toxicity and
laboratory evidence of anti‐melanoma activity. Therefore, it was considered for clinical …
laboratory evidence of anti‐melanoma activity. Therefore, it was considered for clinical …
Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study
PM Fracasso, MF Brady, DH Moore… - Journal of clinical …, 2001 - ascopubs.org
PURPOSE: A phase II study was conducted to determine the efficacy of paclitaxel and
valspodar (PSC 833) in patients with advanced epithelial ovarian cancer. Valspodar, a …
valspodar (PSC 833) in patients with advanced epithelial ovarian cancer. Valspodar, a …